Numis Securities reissued their buy rating on shares of Vectura Group (LON:VEC) in a research report report published on Thursday, March 22nd. The firm currently has a GBX 160 ($2.29) target price on the stock.
VEC has been the subject of a number of other reports. Royal Bank of Canada raised Vectura Group to a sector performer rating and set a GBX 119 ($1.70) target price for the company in a report on Thursday, December 14th. Shore Capital reissued a hold rating on shares of Vectura Group in a report on Wednesday, March 21st. JPMorgan Chase reaffirmed an overweight rating on shares of Vectura Group in a report on Monday, January 15th. Citigroup reaffirmed a buy rating and set a GBX 155 ($2.22) price target on shares of Vectura Group in a report on Tuesday, March 20th. Finally, Peel Hunt dropped their price target on Vectura Group from GBX 160 ($2.29) to GBX 120 ($1.72) and set a hold rating for the company in a report on Wednesday, February 14th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of GBX 139.38 ($2.00).
LON:VEC traded down GBX 7.50 ($0.11) during mid-day trading on Thursday, hitting GBX 97 ($1.39). 11,244,078 shares of the company’s stock traded hands, compared to its average volume of 4,610,000. Vectura Group has a 12 month low of GBX 70 ($1.00) and a 12 month high of GBX 166.97 ($2.39).
Vectura Group plc researches, develops, and commercializes novel therapeutic products and drug delivery systems for the treatment of airways-related diseases. The company's marketed products include Ultibro Breezhaler and Seebri Breezhaler for the treatment of chronic obstructive pulmonary disease (COPD); AirFlusal Forspiro for the treatment of asthma and COPD; ADVATE for the treatment of haemophilia A; and Adept for the treatment of surgical adhesions.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.